RxDoctor Payments Data

Wayne Frederick

Surgical Oncology · Washington, DCNPI 1962408252

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $831,743 of the $831,773 with a category attached, or 100.0%. Insulet Corporation accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $314,752 and has fallen 67.4% since, to $102,500 in 2025.

$831,773in general payments, 2019–2025

Across 24 payments — averaging $34,657 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insulet Corporation$832K
  • Integra Lifesciences Corporation$30

What the payments were for

  • Speaking & faculty fees$831,743100%
  • Food & beverage$300%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insulet Corporation23$831,743
Integra Lifesciences Corporation1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few surgical oncology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.

Other surgical oncology in Washington

See the full list for District of Columbia →

Where these figures come from

Is this you, or does something look wrong? →